Annual Cash & Cash Equivalents
$234.21 M
-$15.57 M-6.23%
31 December 2023
Summary:
Akero Therapeutics annual cash & cash equivalents is currently $234.21 million, with the most recent change of -$15.57 million (-6.23%) on 31 December 2023. During the last 3 years, it has risen by +$46.97 million (+25.08%). AKRO annual cash & cash equivalents is now -6.23% below its all-time high of $249.77 million, reached on 31 December 2022.AKRO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$316.06 M
+$5.71 M+1.84%
30 September 2024
Summary:
Akero Therapeutics quarterly cash and cash equivalents is currently $316.06 million, with the most recent change of +$5.71 million (+1.84%) on 30 September 2024. Over the past year, it has increased by +$46.52 million (+17.26%). AKRO quarterly cash and cash equivalents is now -49.34% below its all-time high of $623.85 million, reached on 31 March 2024.AKRO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKRO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.2% | +17.3% |
| 3 y3 years | +25.1% | +91.6% |
| 5 y5 years | +208.3% | +113.8% |
AKRO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -6.2% | +55.6% | -49.3% | +110.0% |
| 5 y | 5 years | -6.2% | +261.5% | -49.3% | +569.0% |
| alltime | all time | -6.2% | >+9999.0% | -49.3% | +569.0% |
Akero Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $316.06 M(+1.8%) |
| June 2024 | - | $310.36 M(-50.3%) |
| Mar 2024 | - | $623.85 M(+166.4%) |
| Dec 2023 | $234.21 M(-6.2%) | $234.21 M(-13.1%) |
| Sept 2023 | - | $269.55 M(-39.3%) |
| June 2023 | - | $444.16 M(+72.2%) |
| Mar 2023 | - | $257.88 M(+3.2%) |
| Dec 2022 | $249.77 M(+66.0%) | $249.77 M(-33.2%) |
| Sept 2022 | - | $374.00 M(+110.4%) |
| June 2022 | - | $177.73 M(+18.1%) |
| Mar 2022 | - | $150.49 M(+0.0%) |
| Dec 2021 | $150.48 M | $150.48 M(-8.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $164.94 M(+4.7%) |
| June 2021 | - | $157.54 M(-16.2%) |
| Mar 2021 | - | $187.96 M(+0.4%) |
| Dec 2020 | $187.24 M(+189.0%) | $187.24 M(-2.8%) |
| Sept 2020 | - | $192.68 M(+204.6%) |
| June 2020 | - | $63.25 M(+33.9%) |
| Mar 2020 | - | $47.24 M(-27.1%) |
| Dec 2019 | $64.79 M(-14.7%) | $64.79 M(-56.2%) |
| Sept 2019 | - | $147.84 M(-9.1%) |
| June 2019 | - | $162.65 M(+133.0%) |
| Mar 2019 | - | $69.80 M(-8.1%) |
| Dec 2018 | $75.97 M(>+9900.0%) | $75.97 M |
| Dec 2017 | $598.00 K | - |
FAQ
- What is Akero Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akero Therapeutics?
- What is Akero Therapeutics annual cash & cash equivalents year-on-year change?
- What is Akero Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Akero Therapeutics?
- What is Akero Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Akero Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AKRO is $234.21 M
What is the all time high annual cash & cash equivalents for Akero Therapeutics?
Akero Therapeutics all-time high annual cash & cash equivalents is $249.77 M
What is Akero Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AKRO annual cash & cash equivalents has changed by -$15.57 M (-6.23%)
What is Akero Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AKRO is $316.06 M
What is the all time high quarterly cash and cash equivalents for Akero Therapeutics?
Akero Therapeutics all-time high quarterly cash and cash equivalents is $623.85 M
What is Akero Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AKRO quarterly cash and cash equivalents has changed by +$46.52 M (+17.26%)